BG103853A - 5, 6, 7-trisubstituted 4-aminopyridol[2,3-d]pyrimidine compounds - Google Patents

5, 6, 7-trisubstituted 4-aminopyridol[2,3-d]pyrimidine compounds

Info

Publication number
BG103853A
BG103853A BG103853A BG10385399A BG103853A BG 103853 A BG103853 A BG 103853A BG 103853 A BG103853 A BG 103853A BG 10385399 A BG10385399 A BG 10385399A BG 103853 A BG103853 A BG 103853A
Authority
BG
Bulgaria
Prior art keywords
compound
aminopyridol
trisubstituted
pyrimidine compounds
therapeutically effective
Prior art date
Application number
BG103853A
Other languages
Bulgarian (bg)
English (en)
Inventor
Shripad Bhagwat
Richard Perner
Yu GU
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG103853A publication Critical patent/BG103853A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG103853A 1997-04-16 1999-11-03 5, 6, 7-trisubstituted 4-aminopyridol[2,3-d]pyrimidine compounds BG103853A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84348497A 1997-04-16 1997-04-16
PCT/US1998/007201 WO1998046604A1 (en) 1997-04-16 1998-04-13 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
BG103853A true BG103853A (en) 2000-06-30

Family

ID=25290123

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103853A BG103853A (en) 1997-04-16 1999-11-03 5, 6, 7-trisubstituted 4-aminopyridol[2,3-d]pyrimidine compounds

Country Status (19)

Country Link
EP (1) EP0975633A1 (ja)
JP (1) JP2001520654A (ja)
KR (1) KR20010006462A (ja)
CN (1) CN1252069A (ja)
AR (1) AR012437A1 (ja)
AU (1) AU741033B2 (ja)
BG (1) BG103853A (ja)
BR (1) BR9809056A (ja)
CA (1) CA2286592A1 (ja)
CO (1) CO4940470A1 (ja)
HU (1) HUP0001443A3 (ja)
IL (1) IL131617A0 (ja)
NO (1) NO995035L (ja)
NZ (1) NZ337125A (ja)
PL (1) PL336265A1 (ja)
SK (1) SK140099A3 (ja)
TR (1) TR199902550T2 (ja)
WO (1) WO1998046604A1 (ja)
ZA (1) ZA983175B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057040A1 (en) * 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
WO2002064594A2 (en) 2001-02-12 2002-08-22 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
CN107744520A (zh) * 2017-10-25 2018-03-02 南京多宝生物科技有限公司 嘧啶类化合物在制备促进小肠蠕动药物中的应用
CN112209924B (zh) * 2019-07-09 2022-04-05 中国科学院天津工业生物技术研究所 选择性腺苷a1受体拮抗剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774094A (en) * 1953-01-02 1957-05-08 Wellcome Found Improvements in or relating to pyrimidine compounds
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds

Also Published As

Publication number Publication date
KR20010006462A (ko) 2001-01-26
HUP0001443A3 (en) 2001-01-29
IL131617A0 (en) 2001-01-28
PL336265A1 (en) 2000-06-19
CN1252069A (zh) 2000-05-03
EP0975633A1 (en) 2000-02-02
AU741033B2 (en) 2001-11-22
BR9809056A (pt) 2000-08-01
HUP0001443A2 (hu) 2000-10-28
NO995035L (no) 1999-12-15
CO4940470A1 (es) 2000-07-24
WO1998046604A1 (en) 1998-10-22
SK140099A3 (en) 2000-05-16
JP2001520654A (ja) 2001-10-30
TR199902550T2 (xx) 2000-04-21
ZA983175B (en) 1998-10-21
NO995035D0 (no) 1999-10-15
AR012437A1 (es) 2000-10-18
NZ337125A (en) 2001-06-29
CA2286592A1 (en) 1998-10-22
AU7108098A (en) 1998-11-11

Similar Documents

Publication Publication Date Title
MY121047A (en) Bicyclo [2.2.1] heptanes and related compounds
BG103417A (en) Condensed pyrimidine bicyclic derivatives
HUP9901215A3 (en) Microemulsions for use as vehicles for administration of active compounds
CA2316921A1 (en) Aryl fused azapolycyclic compounds
CA2401229A1 (en) Aryl fused azapolycyclic compounds
CA2150123A1 (en) Aminomethylene substituted non-aromatic heterocycles
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
YU11501A (sh) Derivati 4,4,-biarilpiperidina sa aktivnošću na receptor opijata
HUP0002956A3 (en) Use of 4-aminopyrrole[3,2d]pyrimidines for the preparation of pharmaceutical compositions treating diseases related to an excess of neuropeptide y
JO2285B1 (en) Dihydro-benzoic derivatives
CA2293823A1 (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
YU79103A (sh) Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao antagonisti mglur2 i receptora
UA42738C2 (uk) ПОХІДНІ 1,2,4-ТРИАЗОЛО[1,5-а]ПІРИМІДИНІВ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ НАПАДІВ
HUP0003982A3 (en) The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
BG103842A (en) 5,7-disubstituted 4-aminopyrido [2,3-d]pyrimidine compounds and their application as adenosinekinase inhibitors
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
AU5884496A (en) Therapeutic sepsis treatment using antagonists to pthrp
HU9600455D0 (en) Use of quinoxalines combined with protease-inhibiting compounds for producing pharmaceutical compositions for treating hiv infections
BG103853A (en) 5, 6, 7-trisubstituted 4-aminopyridol[2,3-d]pyrimidine compounds
BG103861A (en) 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
PL338680A1 (en) 8-substituted derivatives of 9-h-1,3-dioxolo/4,5-h/2,3-benzoidazepins as inhibitors of ampa/cainate receptors
MY118244A (en) Alfa-amino acid amides, preparation thereof and the therapeutical use thereof
ES2005042A6 (es) Procedimiento de preparar derivados de aminoacidos que tienen actividad sobre el sistema nervioso central.